Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

被引:9
作者
Li, Zheng [1 ,2 ]
Wang, Jun [1 ,2 ]
Ge, Shuai-Shuai [1 ,2 ]
Qiu, Qiao-Cheng [1 ,2 ]
Du, Jia-Hui [3 ]
Shan, Shuang-Shuang [3 ]
Shen, Xiang-Dong [1 ,2 ]
Wan, Chao-Ling [1 ,2 ]
Wang, Bin-Ru [1 ,2 ]
Wu, De-Pei [1 ,2 ]
Qiu, Hui-Ying [1 ,2 ]
Xue, Sheng-Li [1 ,2 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou, Peoples R China
[3] Suzhou Vocat Hlth Coll, Suzhou Key Lab Med Biotechnol, Suzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
venetoclax; azacitidine; midostaurin; t(8; 21); relapsed acute myeloid leukemia; KIT mutation; targeted therapy; MUTATIONS; CANCER; ADULTS;
D O I
10.3389/fonc.2022.841276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhibitor. The venetoclax+HMA strategy is also a notable salvage regimen that achieves good clinical outcomes in the treatment of relapsed or refractory (R/R) AML. However, in our clinical practice, we found that disease progressed rapidly even after venetoclax+azacitidine (AZA) therapy in two relapsed t(8;21) AML patients with KIT mutations. We report for the first time the therapeutic potential of venetoclax+midostaurin as a new combination therapy for relapsed t(8;21) AMLs with KIT mutations showing resistance to venetoclax+AZA therapy. Our ex vivo study also showed that midostaurin alone could inhibit proliferation and induce apoptosis of Kasumi-1 cells (e.g. Midostaurin induced G2 phase cell arrest, down-regulated p-KIT and BCL-2, while Bax protein levels were up-regulated) and observed a synergistic anti effect when the two drugs were combined. Our study shows that the venetoclax+midostaurin regimen may be a promising treatment option for R/R t(8;21) AML with KIT mutations.
引用
收藏
页数:6
相关论文
共 35 条
[21]   Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study [J].
Yu, Guopan ;
Zhang, Yu ;
Jin, Hua ;
Yin, Zhao ;
Weng, Guangyang ;
Yu, Sijian ;
Xu, Na ;
Du, Xin ;
Lin, Dongjun ;
Xiao, Jie ;
Sun, Zhiqiang ;
Zhang, Hongyu ;
Liang, Xinquan ;
Guo, Ziwen ;
Zhao, Weihua ;
Dai, Min ;
Jiang, Xuejie ;
Xuan, Li ;
Shi, Pengcheng .
BLOOD, 2023, 142
[22]   Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax plus Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC) [J].
Daver, Naval G. ;
Wei, Andrew H. ;
Stein, Eytan M. ;
DeAngelo, Daniel J. ;
Pathak, Dhrubajyoti ;
Xu, Yunnan ;
Grzesiak, Stephanie ;
Venditti, Adriano .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S217-S217
[23]   Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML) [J].
Fleming, Shaun ;
Roboz, Gail J. ;
Fathi, Amir T. ;
Zhang, Tian Y. ;
Wei, Andrew ;
Carraway, Hetty E. ;
Holes, Leanne ;
Petrlik, Erica ;
Prebet, Thomas ;
Menezes, Daniel L. ;
Bluemmert, Iryna ;
Sun, Hao ;
Ravandi, Farhad .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S293-S293
[24]   Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review [J].
Jin, Xuelian ;
Liu, Zhigang ;
Wu, Yu ;
Ji, Jie .
FRONTIERS IN IMMUNOLOGY, 2025, 15
[25]   Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report [J].
Tamellini, E. ;
Simio, C. ;
Bernardelli, A. ;
Ferrarini, I. ;
Vatteroni, A. ;
Moioli, A. ;
Macaluso, V. ;
Marchetti, E. ;
Tanasi, I. .
ANNALS OF HEMATOLOGY, 2024, 103 (10) :4309-4311
[26]   Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review [J].
Yahia, Alaa Eldein ;
Motabi, Ibrahim ;
Alsakkaf, Abdullah A. ;
Alzahrani, Kamal ;
Alsuhaibani, Laila M. ;
Albtoosh, Bilal ;
Albathi, Abdullah Khaled ;
Alrajhi, Abdullah M. .
LEUKEMIA RESEARCH REPORTS, 2025, 23
[27]   The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia [J].
Qin, Ya-Zhen ;
Jiang, Qian ;
Wang, Yu ;
Jiang, Hao ;
Xu, Lan-Ping ;
Zhao, Xiao-Su ;
Zhang, Xiao-Hui ;
Liu, Kai-Yan ;
Huang, Xiao-Jun .
BLOOD CANCER JOURNAL, 2021, 11 (04)
[28]   Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial [J].
Ruhnke, Leo ;
Roellig, Christoph ;
Herold, Sylvia ;
Sauer, Tim ;
Brandts, Christian H. ;
Steffen, Bjoern ;
Schaefer-Eckart, Kerstin ;
Krause, Stefan W. ;
Haenel, Mathias ;
Reichle, Albrecht ;
Scholl, Sebastian ;
Neubauer, Andreas ;
Mikesch, Jan-Henrik ;
Schetelig, Johannes ;
Stoelzel, Friedrich ;
Kramer, Michael ;
Haake, Annett ;
Frimmel, Julia ;
Kraemer, Alwin ;
Schlenk, Richard ;
Platzbecker, Uwe ;
Serve, Hubert ;
Baldus, Claudia D. ;
Mueller-Tidow, Carsten ;
Aust, Daniela ;
Bornhaeuser, Martin ;
Ehninger, Gerhard ;
Thiede, Christian .
HAEMATOLOGICA, 2023, 108 (09) :2520-2525
[29]   Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia [J].
Sun, Yuan ;
Wang, Xu ;
Chen, Wen-Min ;
Hao, Yue ;
Li, Ling-Di ;
Li, Jin-Ying ;
Sun, Kai ;
Shi, Zong-Yan ;
Jiang, Hao ;
Jiang, Qian ;
Huang, Xiao-Jun ;
Qin, Ya-Zhen .
HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
[30]   Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax plus Azacitidine Versus Intensive Chemotherapy [J].
Winters, Amanda C. ;
Bosma, Grace ;
Abbott, Diana ;
Minhajuddin, Mohd ;
Jordan, Craig ;
Pollyea, Daniel A. ;
Gutman, Jonathan A. .
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10) :694.e1-694.e9